Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Bill.com Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Bill.com Holdings Inc trades at $39.36 (market cap $4.05B). The key difference: ACADIA Pharmaceuticals Inc. and Bill.com Holdings Inc are close in size by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BILL | |
|---|---|---|
Market Cap | $4.49B | $4.05B |
Sector | Health | Technology |
52-Week High | $28.06 | $56.32 |
52-Week Low | $20.06 | $31.96 |
Enterprise Value | $3.69B | $3.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BILL Holdings trades at $40.68, up 0.49% today, with strong analyst consensus pointing to a $48 price target. The stock shows bullish technical momentum with recent earnings beats and revenue growth from $1.3B to $1.46B in 2025. Recent executive appointments and AI focus signal strategic positioning for growth.
Outlook remains positive with 56% analyst buy ratings and 36% upside potential, though high P/E of 214 and thin net margins of 0.01% pose valuation risks. Key catalysts include continued earnings outperformance and AI integration, while macroeconomic sensitivity and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
